“Lupus Nephritis Pipeline Insight, 2023” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Lupus Nephritis Therapeutics Market.
The report provides a detailed description of the Lupus Nephritis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Lupus Nephritis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing Lupus Nephritis therapies.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lupus Nephritis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging Lupus Nephritis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Lupus Nephritis treatment market.
Lupus Nephritis Therapeutics Analysis
Lupus Nephritis (LN), is one of the most severe organ manifestations of systemic lupus erythematosus (SLE) which is an autoimmune disorder leading to the loss of immune tolerance of endogenous nuclear material resulting in systemic autoimmunity that causes damage to various tissues and organs.
There are different types of lupus nephritis. Treatment is based on the type of lupus nephritis, which is determined by the biopsy. Since symptoms and severity vary from person to person, treatments are individually tailored to meet a person’s particular circumstances.
The current treatment of lupus nephritis is still based on steroids, cyclophosphamide, azathioprine, and mycophenolate mofetil, which are non-selective immunosuppressive drugs that can inhibit multiple components of adaptive immunity. The treatment for LN varies with respect to the severity of the disease.
There are approx. 20+ key companies developing therapies for Lupus Nephritis. Currently, Roche is leading the therapeutics market with its Lupus Nephritis drug candidates in the most advanced stage of clinical development.
Lupus Nephritis Companies in the Therapeutics Market Include:
Roche
Horizon Therapeutics
Equillium
Argenx
AstraZeneca
Novartis
RemeGen
Annexon
And Many Others
Emerging and Marketed Lupus Nephritis Therapies Covered in the Report Include:
Obinutuzumab: Roche
Daxdilimab: Horizon Therapeutics
Itolizumab: Equillium
Secukinumab: Novartis
Guselkumab: Janssen Research & Development
Zanubrutinib: BeiGene
And Many More
Get an in-depth Assessment of the Emerging Therapies and Lupus Nephritis Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight
The Report Covers the Emerging Lupus Nephritis Therapies Under Different Phases of Clinical Development Like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued and inactive candidates
Route of Administration – Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Molecule Type – Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Mechanism of Action of the Emerging Therapies
CD6 antigen inhibitors
Agammaglobulinaemia tyrosine kinase inhibitors
Complement C5 inhibitor
Antibody-dependent cell cytotoxicity
Interleukin-23 subunit p19 inhibitors
PIM3 protein inhibitor
Dendritic cell inhibitor
IL17A protein inhibitors
Request for Sample PDF to Understand More About the Lupus Nephritis Treatment Outlook and Future Perspectives @
Table of Content
1. Report Introduction
2. Executive Summary
3. Lupus Nephritis Current Treatment Patterns
4. Lupus Nephritis – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Lupus Nephritis Late-Stage Products (Phase-III)
7. Lupus Nephritis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Lupus Nephritis Discontinued Products
13. Lupus Nephritis Product Profiles
14. Lupus Nephritis Companies
15. Lupus Nephritis Drugs
16. Dormant and Discontinued Products
17. Lupus Nephritis Unmet Needs
18. Lupus Nephritis Future Perspectives
19. Lupus Nephritis Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Tonsillitis Market
“Tonsillitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Tonsillitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Tonsillitis market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/market-research
